JP2022518527A - パーキンソン病の患者を治療する方法 - Google Patents

パーキンソン病の患者を治療する方法 Download PDF

Info

Publication number
JP2022518527A
JP2022518527A JP2021543164A JP2021543164A JP2022518527A JP 2022518527 A JP2022518527 A JP 2022518527A JP 2021543164 A JP2021543164 A JP 2021543164A JP 2021543164 A JP2021543164 A JP 2021543164A JP 2022518527 A JP2022518527 A JP 2022518527A
Authority
JP
Japan
Prior art keywords
apomorphine
dose
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518527A5 (https=
Inventor
ビルボー，ティエリー
ナヴィア，ブラッドフォード，アルマンド
オラノウ，チャールズ，ウォーレン
Original Assignee
サノヴィオン ファーマシュティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノヴィオン ファーマシュティカルズ インコーポレーテッド filed Critical サノヴィオン ファーマシュティカルズ インコーポレーテッド
Publication of JP2022518527A publication Critical patent/JP2022518527A/ja
Publication of JP2022518527A5 publication Critical patent/JP2022518527A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021543164A 2019-01-28 2020-01-28 パーキンソン病の患者を治療する方法 Pending JP2022518527A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962797660P 2019-01-28 2019-01-28
US62/797,660 2019-01-28
US201962861077P 2019-06-13 2019-06-13
US201962861067P 2019-06-13 2019-06-13
US62/861,077 2019-06-13
US62/861,067 2019-06-13
PCT/US2020/015434 WO2020160005A1 (en) 2019-01-28 2020-01-28 Methods of treating a patient having parkinson's disease

Publications (2)

Publication Number Publication Date
JP2022518527A true JP2022518527A (ja) 2022-03-15
JP2022518527A5 JP2022518527A5 (https=) 2023-02-01

Family

ID=71841403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543164A Pending JP2022518527A (ja) 2019-01-28 2020-01-28 パーキンソン病の患者を治療する方法

Country Status (6)

Country Link
US (1) US20210315882A1 (https=)
EP (1) EP3917502A4 (https=)
JP (1) JP2022518527A (https=)
CA (1) CA3121531A1 (https=)
MX (1) MX2021008986A (https=)
WO (1) WO2020160005A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4578461A3 (en) * 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
WO2023172649A1 (en) * 2022-03-11 2023-09-14 Alexza Pharmaceuticals, Inc. Apomorphine hydrochloride trimethanolate, its polymorphs and its uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542248A (ja) * 2010-11-15 2013-11-21 ロレアル 固形の化粧用メークアップ及び／又はケア組成物
JP2018513869A (ja) * 2015-04-21 2018-05-31 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542248A (ja) * 2010-11-15 2013-11-21 ロレアル 固形の化粧用メークアップ及び／又はケア組成物
JP2018513869A (ja) * 2015-04-21 2018-05-31 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAUSER, ROBERT A. ET AL.: "Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease", MOVEMENT DISORDERS, vol. 31, JPN7023004889, 2016, pages 1366 - 1372, XP055955846, ISSN: 0005232506, DOI: 10.1002/mds.26697 *
WATANABE, YUDAI ET AL.: "Intravenous Administration of Apomorphine Does NOT Induce Long OS Syndrome: Experimental Evidence fr", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 116, JPN6023052143, 2015, pages 468 - 475, XP055728480, ISSN: 0005232505, DOI: 10.1111/bcpt.12343 *

Also Published As

Publication number Publication date
EP3917502A4 (en) 2022-10-12
US20210315882A1 (en) 2021-10-14
WO2020160005A1 (en) 2020-08-06
EP3917502A1 (en) 2021-12-08
MX2021008986A (es) 2021-10-13
CA3121531A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
JP2008069159A5 (https=)
AU2008212005A1 (en) Sustained release ranolazine formulations
JP2016512833A (ja) ウイルス感染症の治療薬としてのベラプロスト異性体
JP7211706B2 (ja) 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
JP2022518527A (ja) パーキンソン病の患者を治療する方法
US20180221315A1 (en) Combination therapy using acamprosate and d-cycloserine
US20180098940A1 (en) Pediatric formulation
US20200179332A1 (en) Methods of preventing progression to type 2 diabetes melitus
US8435963B2 (en) Weight loss compositions and uses thereof
US20240100011A1 (en) Pediatric formulations of ferric citrate
JP2021509409A5 (https=)
EP1732551A1 (en) Perhexilin for treating chronic heart failure
WO2019094434A1 (en) Therapeutic combination for treatment of cerebellar ataxia
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
WO2010087150A1 (ja) 胃酸分泌抑制剤及びカリウムチャンネル阻害剤
JP2008189679A (ja) ２型糖尿病治療用の併用医薬
JP2016130265A (ja) 生体内のメイラード反応抑制剤またはＡＧＥｓ生成抑制剤
JP6465592B2 (ja) 涙液分泌促進組成物
JP2016514125A (ja) バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
JP5982715B2 (ja) 抗高血圧薬組成物
JPWO2009044548A1 (ja) 抗下痢症組成物及びその含有物と下痢症予防方法
US20050272814A1 (en) Medicine for prevention or treatment of diabetes
US20060025478A1 (en) Medicine for prevention or treatment of diabetes
EP1747780A1 (en) Drug for prevention or treatment of diabetes
Menezes et al. Experimental pharmacological agents in the management of Parkinson’s disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210823

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903